Gancotamab

甘妥单抗

Report date: 2024/02/05 14:09:04

Base Information

Drug NameGancotamab

Drug Alias NameAnti-HER2 scFv-PEG-DSPE conjugateNano-doxorubicinGancotamab (Merrimack)MM-302

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Doxorubicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTopoisomerase II inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsTopoisomerase IIReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsOvarian NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumCanada +[9]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesMerrimack Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesGrupo Espanol De Investigacion En Cancer De Ovario

Inactive CompaniesMerrimack Pharmaceuticals Inc

Active IndicationsOvarian Neoplasms

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A